Cosmos Health Inc. announced the launch of Cur18, a clinically studied curcumin formulation, with a U.S. rollout scheduled for the second quarter of 2026. The new product is positioned as a next‑generation nutraceutical for joint health, offering a clean‑label profile derived predominantly from turmeric.
Cur18 delivers up to 39‑fold higher free curcumin bioavailability and 49.5‑fold higher total curcumin area under the curve compared with standard 95 % curcuminoid extracts. The formulation is standardized to approximately 50 % curcuminoids, retains essential oils and polar resins from the turmeric plant, and is self‑affirmed GRAS for safety.
Clinical evidence supports Cur18’s performance: a randomized, double‑blind crossover pharmacokinetic study of 18 subjects and a double‑blind, placebo‑controlled osteoarthritis study of 101 subjects demonstrated significant improvements in knee pain and functional outcomes. The product’s safety profile is consistent with GRAS status.
Strategically, Cur18 expands Cosmos Health’s Sky Premium Life brand into joint health, aligning with the company’s broader goal of broadening its nutraceutical portfolio and leveraging its vertically integrated manufacturing capabilities. The multi‑channel U.S. rollout will include e‑commerce (Amazon), direct‑to‑consumer, specialty retail, and practitioner networks.
The global turmeric market is projected to reach $8.4 billion by 2035, and Cur18 differentiates itself by offering high‑bioavailability without synthetic enhancers, positioning Cosmos Health to capture a share of the growing high‑bioavailability supplement segment.
Greg Siokas, CEO of Cosmos Health, said, "With Cur18, we are introducing a clinically studied, patented formulation designed to enhance bioavailability and deliver meaningful results."
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.